secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001725160-23-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis FY2022 cash $437M, R&D $172.7M; azenosertib RP2D on track for 1H 2023
------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $437.4M as of Dec 31, 2022; projected cash runway into Q2 2025.
- R&D expenses $172.7M for FY2022 (vs $175.6M in 2021); G&A expenses $54.5M (vs $40.9M).
- On track to declare azenosertib monotherapy RP2D in 1H 2023; Cyclin E1 enrichment strategy in ovarian cancer.
- Appointed Iris Roth, PhD as Chief Operating Officer in February 2023.
- Initiated enrollment in Phase 1/2 azenosertib + BEACON regimen (Pfizer) in BRAF V600E mCRC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000047/0001725160-23-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000047/zntl-20230301.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer